Iodine-131 Therapy After Surgery for Low-Risk Thyroid Cancer

You have been diagnosed with thyroid cancer. You have undergone surgery. What happens next? Do you need Iodine-131 therapy? Do you need an Iodine-131 scan? And what is the role of thyroglobulin?

These are some of the most common questions patients ask after surgery for differentiated thyroid cancer.

The good news is that not every patient with thyroid cancer needs radioactive iodine therapy.

The 2025 American Thyroid Association (ATA) guidelines place increasing emphasis on risk-adapted and individualized treatment, with the aim of avoiding unnecessary treatment in patients who have an excellent prognosis while identifying those who may benefit from additional therapy. (PubMed)

Let us take a typical example.

Suppose you have a well-differentiated thyroid cancer, such as papillary or follicular thyroid cancer, which is small—for example, less than 2 cm—and there is no evidence of lymph-node or distant metastasis.

After surgery, if the final pathology does not show other unfavorable features, you may fall into the low-risk category.

In such patients, the next step is not automatically radioactive iodine therapy.

Instead, we need to look carefully at the postoperative findings and assess whether there is any evidence of residual or recurrent disease.

The 2025 ATA guidelines have further refined the risk-stratification system into four categories:

• Low risk
• Low-intermediate risk
• Intermediate-high risk
• High risk

This allows treatment to be individualized rather than giving radioactive iodine routinely to everyone. (American Thyroid Association)

Not necessarily.

For appropriately selected low-risk patients, radioactive iodine (RAI) can be omitted.

This is an important change in the way we think about thyroid cancer treatment. Radioactive iodine is a very effective treatment when it is indicated, but it is not automatically necessary simply because someone has had thyroid cancer.

The purpose of RAI should be clearly defined.

It may be used to:

• destroy residual normal thyroid tissue (remnant ablation),
• treat known or suspected residual thyroid cancer (adjuvant or therapeutic RAI), or
• treat iodine-avid metastatic disease.

In a patient with genuinely low-risk disease and no evidence of residual disease, the potential benefits of RAI may be very small, and observation may be the better option.

The 2025 ATA guidelines therefore emphasize individualized decision-making and de-escalation of treatment in appropriately selected low-risk patients. (DOI.org)

This is where thyroglobulin—or Tg—becomes very important.

Thyroglobulin is a protein produced by normal thyroid cells as well as differentiated thyroid cancer cells.

After a total thyroidectomy, there should be very little thyroid tissue left. Therefore, the amount of Tg detectable in the blood can provide useful information about whether there may be residual thyroid tissue or thyroid cancer.

However, Tg must always be interpreted together with thyroglobulin antibodies (TgAb).

Why?

Because Tg antibodies can interfere with the measurement and make the Tg result difficult to interpret.

The 2025 ATA guidelines recommend that TgAb be measured whenever Tg is measured. (PubMed Central (PMC))

There are two ways of measuring thyroglobulin.

1. Non-stimulated Tg

This is measured while you are taking thyroid hormone replacement.

1. Stimulated Tg

Here, we deliberately increase your TSH level because TSH stimulates thyroid cells—and thyroid cancer cells—to produce more thyroglobulin.

TSH stimulation can be achieved either by:

• temporarily stopping , sometimes using short-term T3 supplementation before withdrawal, or
• administering recombinant human TSH (rhTSH).

When thyroid hormone is withdrawn, TSH generally rises to above approximately 30 mIU/L, providing adequate stimulation for Tg measurement. (PubMed Central (PMC))

However, an important point is that stimulated Tg is not necessarily required in every low-risk patient. The 2025 ATA approach increasingly uses postoperative Tg measured on thyroid hormone therapy, together with TgAb and imaging findings, to determine whether additional evaluation or treatment is required. (PubMed Central (PMC))

A common misconception is:

“I have had thyroid cancer, so I must undergo an Iodine-131 whole-body scan.”

That is not true for every patient.

The 2025 ATA guidelines specifically state that patients who have undergone lobectomy or total thyroidectomy without RAI should not undergo surveillance radioiodine whole-body scanning routinely.

Similarly, patients with low or low-intermediate recurrence risk who demonstrate an excellent response to treatment do not require routine diagnostic radioiodine whole-body scanning during follow-up. (PubMed Central (PMC))

This is because a diagnostic iodine scan may have limited value when there is no clear clinical or biochemical suspicion of residual disease.

In many low-risk patients, neck ultrasound and serum Tg/TgAb provide more useful information.

A common misconception is:

“I have had thyroid cancer, so I must undergo an Iodine-131 whole-body scan.”

That is not true for every patient.

The 2025 ATA guidelines specifically state that patients who have undergone lobectomy or total thyroidectomy without RAI should not undergo surveillance radioiodine whole-body scanning routinely.

Similarly, patients with low or low-intermediate recurrence risk who demonstrate an excellent response to treatment do not require routine diagnostic radioiodine whole-body scanning during follow-up. (PubMed Central (PMC))

This is because a diagnostic iodine scan may have limited value when there is no clear clinical or biochemical suspicion of residual disease.

In many low-risk patients, neck ultrasound and serum Tg/TgAb provide more useful information.

Suppose the postoperative assessment raises concern.

For example:

• Tg is higher than expected or rising,
• TgAb is elevated or increasing,
• neck ultrasound shows a suspicious lymph node,
• or there are other clinical or pathological features suggesting persistent disease.

In such circumstances, further evaluation may be appropriate.

Depending on the individual situation, this can include:

• high-quality ultrasound of the neck
• diagnostic radioiodine imaging
• SPECT/CT
• CT/MRI
• or, in selected higher-risk patients, FDG PET/CT.

The choice depends on the patient’s original pathology, risk category, Tg/TgAb results and imaging findings.

If radioiodine imaging is required, the 2025 ATA guidelines allow the use of Iodine-123 or low-activity Iodine-131, with SPECT/CT used when appropriate to localize areas of radioiodine uptake more accurately. (PubMed Central (PMC))

This is an important situation.

After total thyroidectomy, some normal thyroid tissue may remain in the thyroid bed. This is called thyroid remnant tissue.

Finding a small remnant does not automatically mean that you have cancer.

If there is only a small thyroid remnant and there are no suspicious lymph nodes or other evidence of disease, the management may still be observation rather than radioactive iodine therapy, depending on the overall clinical picture.

This is one of the reasons why we should not automatically equate “radioiodine uptake” with “cancer.”

If Tg is significantly elevated, rising over time, or accompanied by concerning TgAb trends, we become more suspicious of residual or recurrent disease.

The 2025 ATA response-to-therapy framework uses Tg thresholds that depend on whether the patient has undergone total thyroidectomy alone or total thyroidectomy followed by RAI.

For example, after total thyroidectomy without RAI, an unstimulated Tg below approximately 2.5 ng/mL with undetectable TgAb, together with reassuring imaging, can be consistent with an excellent response. After total thyroidectomy with RAI, the corresponding Tg threshold is lower—approximately 0.2 ng/mL. (PubMed Central (PMC))

Therefore, one number should never be interpreted in isolation.

The trend in Tg, TgAb status, ultrasound findings, original pathology and the patient’s recurrence-risk category all need to be considered together.

This is perhaps the most important point.

If you have low-risk thyroid cancer, it does not mean that you can simply forget about the disease after surgery.

It means that your risk of recurrence is sufficiently low that we may be able to avoid unnecessary radioactive iodine treatment and unnecessary radiation exposure, provided your postoperative assessment is reassuring.

At the same time, we need appropriate surveillance.

The 2025 ATA guidelines recommend a more individualized approach to follow-up, with serum Tg/TgAb and neck ultrasound used according to the patient’s treatment and response. In low-risk patients who have had total thyroidectomy without RAI and demonstrate an excellent response, an unstimulated Tg below 2.5 ng/mL with negative TgAb and reassuring imaging supports a de-escalated surveillance strategy. (PubMed Central (PMC))

If you have a small, well-differentiated thyroid cancer with no lymph-node or distant metastasis, radioactive iodine is not automatically required.

The next step is to carefully assess:

1. What did the final pathology show?
2. What is your ATA recurrence-risk category?
3. What is your postoperative thyroglobulin level?
4. Are thyroglobulin antibodies present or increasing?
5. What does the neck ultrasound show?

Based on these findings, we decide whether you need:

Observation → further imaging → diagnostic radioiodine imaging → or radioactive iodine therapy.

The important message is that not every low-risk thyroid cancer patient needs Iodine-131 therapy, and not every low-risk patient needs a diagnostic Iodine-131 scan.

But low risk does not mean “no evaluation.”

It means appropriate evaluation followed by the least intensive treatment necessary for your individual risk.

That is the essence of modern thyroid cancer management: treat the patient, not just the diagnosis.